Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01821378 · ClinicalTrials.gov registry record · Phase 3
Lurasidone Low-Dose - High-Dose Study Study
A Phase 3 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 412
- Enrollment target
NCT01821378 is a Phase 3 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 412 participants.
The verdict
NCT01821378, a Phase 3 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 412 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the efficacy of lurasidone 20 mg/day in subjects with an acute exacerbation of schizophrenia.
Interventions
- DRUG Placebo
- DRUG Lurasidone
- DRUG Lurasidone 80 mg once daily initially rerandomized either to 80 mg or 160 mg at week 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 412 participants |
| Start Date | 2013-05 |
| Est. Completion | 2014-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01821378
The ClinicalTrials.gov registry entry for NCT01821378 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 412 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01821378 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01821378 about?
NCT01821378 is a clinical study titled "Lurasidone Low-Dose - High-Dose Study Study". The primary purpose of this study is to evaluate the efficacy of lurasidone 20 mg/day in subjects with an acute exacerbation of schizophrenia.
What is the current status of trial NCT01821378?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 412 participants. The study started on 2013-05. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01821378?
The interventions under investigation include: Placebo (DRUG), Lurasidone (DRUG), Lurasidone 80 mg once daily initially rerandomized either to 80 mg or 160 mg at week 2 (DRUG).
Who is sponsoring clinical trial NCT01821378?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.